AZN AstraZeneca Plc
AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respiratory. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Company profile
Ticker
AZN
Exchange
Website
CEO
Pascal Soriot
Employees
Location
Fiscal year end
Sector
Industry (SEC)
Former names
Zeneca Group PLC
SEC CIK
Corporate docs
AZN stock data
()
Calendar
3 Mar 20
11 Jul 20
31 Dec 20
News
Company financial data Financial data
Recent insider trades
| Date | Owner | Security | Transaction | Code | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|
| 19 Dec 19 | AstraZeneca | Common Stock | Buy | Aquire P | No | 0 | 12,946,900 | 0 | 12,946,900 |
| 7 Oct 19 | AstraZeneca | Common Stock | Buy | Aquire P | No | 19 | 425,000 | 8.08M | 14,650,334 |
| 7 Oct 19 | AstraZeneca | Common Stock | Conversion | Aquire C | No | 0 | 14,225,324 | 0 | 14,225,334 |
| 7 Oct 19 | AstraZeneca | Series A-1 Preferred Stock Common Stock | Conversion | Dispose C | No | 0 | 14,225,324 | 0 | 0 |
Institutional ownership Q4 2019
13F holders |
Current |
|---|---|
| Total holders | 0 |
| Opened positions | 0 |
| Closed positions | 1 |
| Increased positions | 0 |
| Reduced positions | 0 |
13F shares |
Current |
|---|---|
| Total value | 0 |
| Total shares | 0 |
| Total puts | 0 |
| Total calls | 0 |
| Total put/call ratio | – |
Largest owners |
Shares | Value |
|---|
Financial report summary
?
Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
6th grade Avg
|
|
New words:
accuracy, alter, antagonist, Asia, atenolol, belong, Brexit, Breztri, Building, built, chemoradiation, chlorthalidone, chronic, CLL, communicated, communicating, communication, comparison, complex, constipation, critical, CVOT, DBTCA, dealing, depend, Description, Deutsche, device, dipeptidyl, directed, DOJ, Duaklir, earlier, effort, erosion, ESPC, fiscal, forecasted, formulary, headroom, heavily, highly, historical, hospital, hydrochlorothiazide, identification, Inderal, inflation, inquiry, intervene, Israel, Italy, judgement, judgment, jurisdiction, leukaemia, likelihood, lisinopril, long, lymphocytic, mandated, manner, Medicare, method, methodology, monitoring, mortality, naloxegol, NHSA, OIC, outcome, Pacific, PAMORA, peak, peripherally, point, Prasco, processed, procurement, projected, propranolol, protein, Purpose, quantified, range, realised, reappointment, recognise, recognised, reconciling, recoverability, recoverable, RedHill, regaining, relied, retail, retrospective, role, segment, sensitive, sensitivity, skill, SLL, slower, small, software, sought, specialised, successor, tam, technical, Tenoretic, Tenormin, transport, trust, turn, unauthorised, uncontrolled, unexpected, unlawful, unsettled, variable, whistleblower, Zestoretic, Zestril
Removed:
Achieve, acquired, addressed, adjusted, adjustment, agree, alliance, Almirall, amortisation, amounting, applied, approve, arose, arrive, asset, auditing, balance, BMS, bond, broadly, calculated, chemotherapy, CHMP, column, comparative, copy, cost, credit, daily, decision, decrease, deferred, depreciation, detailed, disagreement, disclaimer, dismissed, disposal, divided, dollar, element, employer, ending, EPS, euro, Excluded, Externalisation, fair, finance, foregoing, formal, furnish, hedging, herewith, HQ, invest, investment, joint, June, KPMG, low, lower, manufacturing, margin, MedImmune, modified, olaparib, option, organisation, owing, participated, principally, proceeding, prohibited, propose, proposed, PwC, receivable, reduced, remeasurement, removing, repaid, reportable, requested, resolved, Rest, restructuring, retirement, rotation, royalty, satisfaction, scientific, scope, serve, spend, stating, transfer, trial, UKLA, unauthorized, unsuccessful, unwind, venture, York, ZS
Financial reports
20-F
2019 FY
Annual report (foreign)
3 Mar 20
20-F
2018 FY
Annual report (foreign)
5 Mar 19
20-F
2017 FY
Annual report (foreign)
6 Mar 18
20-F
2016 FY
Annual report (foreign)
7 Mar 17
20-F
2015 FY
Annual report (foreign)
8 Mar 16
20-F
2014 FY
Annual report (foreign)
10 Mar 15
20-F
2013 FY
Annual report (foreign)
20 Mar 14
20-F
2012 FY
Annual report (foreign)
25 Mar 13
20-F/A
2011 FY
Annual report (foreign) (amended)
21 Sep 12
20-F
2011 FY
Annual report (foreign)
28 Mar 12
Current reports
6-K
Brilinta Granted Us Fda Priority Review for Stroke
9 Jul 20
6-K
Lynparza Approved In the Eu for Brca- Mutated Metastatic Pancreatic Cancer
8 Jul 20
6-K
Total Voting Rights
1 Jul 20
6-K
Director/pdmr Shareholding
30 Jun 20
6-K
Selumetinib Granted Orphan Drug Designation In Japan for Neurofibromatosis Type 1
30 Jun 20
6-K
Holding(s) In Company
17 Jun 20
6-K
Holding(s) In Company
17 Jun 20
6-K
Astrazeneca to Supply Europe with Up to 400 Million Doses of Oxford University's Vaccine at No Profit
15 Jun 20
6-K
Emtn Programme Routine Technical Update: Publication of Prospectus
11 Jun 20
6-K
Total Voting Rights
1 Jun 20
Registration and prospectus
F-6
Registration for ADRs (foreign)
22 Jan 20
F-3ASR
Automatic shelf registration (foreign)
8 Nov 19
25-NSE
Exchange delisting
18 Sep 19
25-NSE
Exchange delisting
16 Nov 18
25-NSE
Exchange delisting
16 Nov 18
8-A12B
Registration of securities on exchange
17 Aug 18
424B2
Prospectus for primary offering
16 Aug 18
FWP
Free writing prospectus
15 Aug 18
S-8
Registration of securities for employees
14 Aug 18
FWP
Free writing prospectus
14 Aug 18
Proxies
No filings
Other
IRAN
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
3 Mar 20
EFFECT
Notice of effectiveness
7 Feb 20
IRAN
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
5 Mar 19
IRAN
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
6 Mar 18
CERTNYS
Certification of approval for NYSE listing
14 Jun 17
IRAN
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
8 Mar 17
IRAN
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
8 Mar 16
CERTNYS
Certification of approval for NYSE listing
18 Nov 15
IRAN
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
10 Mar 15
EFFECT
Notice of effectiveness
5 Dec 14
Ownership
4
Change in insider ownership
7 Feb 20
3
Initial statement of insider ownership
7 Feb 20
SC 13D
Beneficial ownership report
7 Feb 20
SC 13G/A
Beneficial ownership report (amended)
5 Feb 20
SC 13G
Viela Bio, Inc.
30 Jan 20
SC 13G/A
Astrazeneca PLC
27 Jan 20
SC 13D
Innate Pharma SA
25 Oct 19
4
Change in insider ownership
9 Oct 19
3/A
Initial statement of insider ownership (amended)
9 Oct 19
3
Initial statement of insider ownership
3 Oct 19